Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
April 25, 2017 10:10 AM 2 min read

5 Concerns Express Scripts Confirmed With Its Announcement It Will Likely Lose Anthem Business

by Wayne Duggan Benzinga Staff Writer
Follow

Express Scripts Holding Company (NASDAQ:ESRX) shares are down more than 13 percent after the company announced it is likely losing Anthem Inc (NYSE:ANTM), its largest client, after Anthem’s current contract ends in 2019.

Growing Concerns

The news is obviously a blow to Express’s business, but Baird analyst Eric Coldwell says the news shouldn’t come as a surprise. Anthem has sued Express claiming that is has been overcharged for services in the past. Anthem currently accounts for about a third of Express’s EBITDA. For now, Coldwell says Express without Anthem is worth around $53 per share.

“Unless Anthem is behaving irrationally, this says things about ESRX and about the PBM industry: either another PBM is promising massive savings — so much so that ANTM will wait three years and absorb an implementation headwind—or ANTM thinks it can do better on its own or with a hybrid model,” Coldwell explained.

Coldwell said Express confirmed five fears Baird had about the stock prior to the announced loss of Anthem:

    1. Anthem accounted for 33 percent of Express earnings and was growing much faster than the rest of Express’ business.
    2. Express is overearning on a per-share basis.
    3. Without Anthem and other transitioning clients, Coldwell projects long-term growth for Express’ core business at just 2–4 percent.
    4. Express’ desire to be independent seemingly limits the potential of M&A growth.
    5. The loss of Anthem single-handedly altered Baird’s projected 2020 EPS projections for Express from $9.1 to $5.56.

In Conclusion...

For now, Coldwell says even short-term traders should stay away from Express until it hits the low $50s.

Baird maintains a Neutral rating for Express but has lowered its price target from $73 to $53.

Related Links: Salary? What's A Salary? The Highest Paid Execs By Stock Holdings

Could Pharmacy Benefit Managers Be Trump's Next Target?

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
Analyst ColorBiotechNewsShort IdeasHealth CareRumorsContractsAnalyst RatingsMoversTrading IdeasGeneralBaird
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Comments
Loading...